Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis CKASL clinical practice guidelines: management of hepatitis CRibavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominanceHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsChronic hepatitis C: future treatmentMiR-122 in hepatitis B virus and hepatitis C virus dual infectionDaclatasvir: potential role in hepatitis CDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisChimeric mouse model for the infection of hepatitis B and C virusesNS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data.Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patientsAsunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressantDirect-acting antiviral agents and the path to interferon independence.A cutting-edge view on the current state of antiviral drug development.Current and future therapies for hepatitis C virus infection.Direct-acting antiviral agents for hepatitis C virus infection.Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise reviewEffect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infectionBaseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosisPrevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyInfluencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patientsDirect-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?
P2860
Q24628717-841671EA-0713-4FEF-A690-55DFD73FA5B3Q26745769-3D3F2CDC-130D-43A5-859C-7B2BED4F4755Q26752471-B8716A46-5DB2-4203-A651-BBB777217E98Q26777659-2799071D-3E54-4788-8F96-B6E2B2DC920AQ26782405-7D64E428-8699-46FA-87B0-D6F9EC96F824Q26798477-67288368-B7AA-4B47-ACA8-89DD503BAF3CQ26824075-A768D011-E31B-4FD4-B197-6E057B664405Q27008894-069C8CD5-D7F6-4FC0-97D0-79BFCD4AF801Q27012741-D756CB07-73C4-44E7-AC5A-EA80AC9F89B3Q28077287-753877B2-2667-4F74-AA64-72CD7E11161FQ28534370-1208E6FC-0AB1-412B-B7B1-35E82954B69FQ30352718-105DD5DB-FBE8-4233-91CF-D58EDEE0EC45Q30402571-CDF545E4-82D5-4558-BD0C-A65B072B9557Q30843427-9B972B45-9E20-4FCF-AEFF-BE6A64B77875Q31051529-4BE2846A-BA4A-4D61-B91D-F9FFC84AA248Q31170657-6F59E571-C796-414C-8E70-E636D9D29B2BQ33410537-1F18CBC3-A8F0-4074-BC01-67BAFEA073C2Q33576524-D323F9E3-9B85-4910-B132-819AE8271763Q33581167-64895283-8D8E-4F6D-9D31-74C25279926EQ33622970-A4CFB45E-8366-4E35-8CE5-AC1819892423Q33710278-6070E530-38C2-47E9-A538-C894ABC341A1Q33727347-D6B73A92-DC9B-4B56-A1E0-BBBD2C048EBEQ34036018-D9395207-4157-4B8B-AA78-9A9CCD4333C2Q34036762-91C7EE2A-C688-4E4F-B6EB-7942E18A5E12Q34321440-067C705A-3E88-45EF-B249-FD86DE0D9ADFQ34439125-22BCAF04-8838-4434-8701-972EE44AE2B4Q34467312-FD3A0B1C-16E4-499B-A6A2-8D5B47AC8026Q34532854-8A6C504F-E748-4D41-8C7B-42636357F4D9Q34679526-D4729E6E-0EE1-4215-80B4-85A5A0D73871Q34725990-19F5262B-B6E5-4153-8FC4-C81AA8F8D7CCQ34746864-1F45609C-95E7-422A-A0D4-1AED84FEBDAFQ34926607-41682CFB-F370-4F2F-999B-AFCD047EEECAQ34998753-DF59D76D-4256-4E37-AB62-B7068350D6D6Q35044909-38C6EC3E-37F3-4DB6-91DF-89E53F8ED474Q35070933-81F67C03-71D6-4C2A-86F9-31F33AB8D8F9Q35135565-46F45843-ACFF-4CE0-AFBD-0E0E2BCC18D8Q35592257-631102AC-3C6A-45A9-B98B-F1AF90D85ED4Q35749489-2C135D9E-05D6-42D7-8E97-F8D8D91327F4Q35905985-5EC002F3-5562-4BC5-BACD-195A0211179FQ35947900-32E54340-F854-43B9-ABE6-195A1F91729B
P2860
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@en
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@nl
type
label
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@en
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@nl
prefLabel
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@en
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@nl
P2093
P2860
P356
P1433
P1476
Dual therapy with the nonstruc ...... e 1b-infected null responders.
@en
P2093
Eric Hughes
Fiona McPhee
Hideaki Watanabe
Hiroki Ishikawa
Hiromitsu Kumada
Joji Toyota
Kazuaki Chayama
Kenji Ikeda
Shoichi Takahashi
Yoshiyasu Karino
P2860
P304
P356
10.1002/HEP.24724
P407
P577
2012-01-30T00:00:00Z